Novo Nordisk's Ozempic and Wegovy now available in U.S.

Ozempic, Wegovy move closer to no longer being in shortage, FDA says
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication "off-label" for weight loss, as is permissible by the FDA.
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.
Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several other conditions.
UPDATED: FDA lists all doses of Novo's Wegovy as available, signaling potential end to semaglutide supply rout in US
Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | The FDA this week revised its shortage list to note that the .
Novo takes big step toward ending Ozempic, Wegovy shortages
All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned patients may still experience "variability" filling their prescriptions.
Ozempic and Wegovy considered ‘available’ after more than two years in shortage
The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years after being declared in shortage by the Food and Drug Administration (FDA). While the drugs remain on the shortage list for now,
Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times.
Wegovy's creator invested £6bn in this town. So why is it not booming?
Europe's most valuable company has invested billions in Kalundborg on Denmark's coast - but it has many problems.
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...
Healthy Returns: Wegovy may reduce knee pain in patients with a type of arthritis and obesity
Novo Nordisk’s drug helped reduce knee pain in osteoarthritis patients with obesity. Meanwhile, the Change Healthcare breach ...
Ozempic, Wegovy might help ease knee arthritis pain
People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...
Medpage Today on MSN3d
Wegovy Reduced Pain From Knee Osteoarthritis
Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a ...
Bariatric surgeries drop sharply as people turn to Wegovy, Saxenda for weight loss
The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...
Ozempic, Wegovy might lower Alzheimer's risk in Type 2 diabetics
People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared ...
STAT2d
With new Wegovy data in hand, Novo Nordisk will file for approval in MASH
Novo Nordisk’s Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, new data show.